STAAR Surgical Company

Equities

STAA

US8523123052

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2025-12-11 pm EST			5-day change	1st Jan Change
24.68 ^USD	+2.88%		-7.22%	+1.61%

Dec. 11	Broadwood Partners Sends an Email to Stockholders of STAAR Surgical Company	CI
Dec. 11	Broadwood Partners Issues an Investor Presentation to Shareholders of STAAR Surgical Company	CI

Independent Poxy Advisory Firms Issues Recommendations to Shareholders of Broadwood Partners

Published on 10/16/2025 at 02:05 pm EDT

S&P Capital IQ

STAAR Surgical Company

+2.88%

Alcon Inc.

-1.59%

On October 16, 2025, Broadwood Partners L P announced that independent proxy advisory firm recommended the shareholders of STAAR Surgical Company to vote against the Company's proposed acquisition by Alcon Inc, joining Glass, Lewis & Co., LLC and Egan-Jones Ratings Company at the special meeting of shareholders scheduled to be held on October 23, 2025. In addition, Broadwood Partners recommended the shareholders of the Company to vote against the Company's proposed acquisition by Alcon Inc at the special meeting of shareholders.

Stocks mentioned in the article

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Price	Change	5d. change	Capi.
	STAAR SURGICAL COMPANY	24.68USD	+2.88%	-7.22%	1.23B
	ALCON INC.	63.00CHF	-1.59%	-0.69%	38.96B

Latest news about STAAR Surgical Company

Dec. 11	Broadwood Partners Sends an Email to Stockholders of STAAR Surgical Company	CI
Dec. 11	Broadwood Partners Issues an Investor Presentation to Shareholders of STAAR Surgical Company	CI
Dec. 11	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Dec. 11	Sector Update: Health Care	MT
Dec. 11	STAAR Surgical Sets the Record Straight Regards its Robust Go-Shop Process	CI
Dec. 11	STAAR Surgical Sets the Record Straight Regards its Robust Go-Shop Process	CI
Dec. 11	STAAR Surgical Says No 'Credible Buyer' During Go-Shop Process in Alcon Deal	MT
Dec. 11	STAAR Surgical Investor Broadwood Partners Says Alcon's Proposed Acquisition Remains 'Unfair' to Shareholders	MT
Dec. 11	Broadwood Partners Comments on STAAR Surgical Board Dissent on the Revise Sale to Alcon	CI
Dec. 11	Broadwood Partners comments on STAAR Surgical board dissent on revised sale to Alcon	RE
Dec. 10	Yunqi Capital Comments on STAAR Surgical?s Go-Shop Process	CI
Dec. 10	STAAR Surgical Engages with its Employees	CI
Dec. 10	Sector Update: Health Care Stocks Rise Premarket Wednesday	MT
Dec. 10	STAAR Surgical Engages with its Employees	CI
Dec. 10	STAAR Surgical Engages with its Employees	CI
Dec. 10	STAAR Surgical Acquisition by Alcon Opposed by Investor Yunqi Capital	MT
Dec. 10	Yunqi Capital comments on Staar Surgical's go-shop process and Alcon's revised offer	RE
Dec. 09	Broadwood Partners Still Opposes Alcon's Higher Bid for Staar Surgical	DJ
Dec. 09	Broadwood Partners Responds to Alcon?s Increase to Acquisition Price of STAAR Surgical	CI
Dec. 09	Broadwood Partners continues to urge Staarr shareholders to vote "against" proposed transaction with Alcon	RE
Dec. 09	Swiss Market Index Retreats; Swiss Re Shares Down	MT
Dec. 09	STAAR Surgical Company Enters into Amendment to the Agreement and Plan of Merger with Alcon	CI
Dec. 09	STAAR Surgical Company Enters into Amendment to the Agreement and Plan of Merger with Alcon	CI
Dec. 09	STAAR Surgical Company Enters into Amendment to the Agreement and Plan of Merger with Alcon	CI
Dec. 09	Staar Surgical Shares Surge as Alcon Boosts its Buyout Price	DJ

Chart STAAR Surgical Company

Duration

Period

STAA: Dynamic Chart

Company Profile

STAAR Surgical Company designs, develops, manufactures, and sells implantable lenses for the eye and accessory delivery systems used to deliver the lenses into the eye. These lenses provide visual freedom for patients, lessening or eliminating the reliance on glasses or contact lenses. The Company is a manufacturer of lenses used worldwide in corrective or refractive surgery. It sells its products in approximately 75 countries, with direct distribution in Japan, Germany, Spain, the United States, Canada, the United Kingdom, and Singapore, with a combination of direct distribution and independent distribution in China, Korea, India, France, Benelux, and Italy. The Company markets and sells ICLs for refractive surgery to treat myopia (nearsightedness) as its EVO family of lenses. The Companyâs EVO family of lenses includes its EVO ICL, EVO+ ICL, and EVO Visian ICL. The Company also markets and sells an ICL lens to treat hyperopia (farsightedness), which is called Visian ICL.

Employees

1,157

Sector

Medical Equipment, Supplies & Distribution

Calendar

Feb. 24 - Q4 2025 Earnings Release (Projected)

More about the company